Trials / Recruiting
RecruitingNCT05848258
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 380 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3871801 | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2023-05-23
- Primary completion
- 2026-02-01
- Completion
- 2026-07-01
- First posted
- 2023-05-08
- Last updated
- 2025-12-09
Locations
57 sites across 10 countries: United States, Argentina, Czechia, France, Germany, Hungary, India, Mexico, Poland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05848258. Inclusion in this directory is not an endorsement.